Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of PCVX is 109 and suggests 100% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell